Skip to main content
CStone Pharmaceuticals logo

CStone Pharmaceuticals — Investor Relations & Filings

Ticker · 2616 ISIN · KYG2588M1006 LEI · 300300095A57F80T2461 HKEX Manufacturing
Open in API
Filings indexed 3,374 across all filing types
Latest filing 2020-09-30 Capital/Financing Update
Country KY Cayman Islands
Listing HKEX 2616

About CStone Pharmaceuticals

http://www.cstonepharma.com

CStone Pharmaceuticals is an innovation-driven biopharmaceutical company focused on the research, development, and commercialization of anti-tumor drugs. The company is dedicated to addressing the unmet medical needs of cancer patients globally. Its core therapeutic focus is on innovative immuno-oncology and molecularly targeted therapies. The R&D pipeline is strategically balanced, featuring potential first-in-class or best-in-class assets, including Antibody-Drug Conjugates (ADC) and multi-specific antibodies. CStone has successfully launched four innovative drugs and secured multiple New Drug Application and indication approvals.

Recent filings

Filing Released Lang Actions
INSIDE INFORMATION - ISSUE OF SUBSCRIPTION SHARES UNDER GENERAL MANDATE AND STRATEGIC COLLABORATION WITH PFIZER INVESTMENT
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the issue of subscription shares under a general mandate and a strategic collaboration agreement with Pfizer Investment. It details the terms of a share subscription agreement, the strategic collaboration, subscription price, conditions precedent, and other related information. The content focuses on a capital raising event and strategic partnership rather than financial results, management changes, or regulatory filings. The document is lengthy (15,000 characters) and contains substantive details about the financing transaction and collaboration terms. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2020-09-30 English
ANNOUNCEMENT ON THE PARTICIPATION IN 2020 ONLINE COLLECTIVE RECEPTION ACTIVITY FOR INVESTORS
Regulatory Filings Classification · 95% confidence The document is an announcement about the company's participation in an online collective reception activity for investors, organized by regulatory and industry bodies. It describes the event details, participants, and how investors can join. The document is short (2823 characters) and does not contain any financial data, financial statements, or detailed report content. It is not a financial report, earnings release, or management discussion. It is an announcement related to investor communication and corporate governance transparency but does not fit into categories like Investor Presentation or Management Reports because it is about an event participation rather than a presentation or report. It is also not a regulatory filing in the strict sense of compliance or certification. Given the nature and length, this is best classified as a Regulatory Filing (RNS) as a general announcement that does not fit other categories.
2020-09-25 English
VOLUNTARY ANNOUNCEMENT - CSTONE ANNOUNCES RESULTS FROM TWO STUDIES OF ANTI-PD-1 MONOCLONAL ANTIBODY CS1003 AT THE 2020 ESMO ANNUAL MEETING
Regulatory Filings Classification · 90% confidence The document is a voluntary announcement by CStone Pharmaceuticals reporting results from two Phase 1 clinical studies of their anti-PD-1 monoclonal antibody CS1003 presented at the 2020 ESMO Annual Meeting. It contains detailed clinical trial data, safety and efficacy results, and commentary from the Chief Translational Medicine Officer. There is no indication that this is a full financial report, audit, or regulatory filing. It is not a transcript, capital update, or governance information. The document is a standalone announcement of clinical study results, which does not fit into the typical financial or regulatory categories but is a voluntary announcement of scientific/clinical data. Given the content and context, the best fitting category is Regulatory Filings (RNS) as a general announcement that does not fit other specific categories.
2020-09-25 English
INTERIM REPORT 2020
Interim / Quarterly Report Classification · 100% confidence The document is titled '2020 Interim Report' and contains detailed financial statements such as condensed consolidated statements of profit or loss, financial position, changes in equity, cash flows, and notes to the financial statements. It also includes management discussion and analysis, business highlights, and corporate information. The presence of actual financial data and comprehensive analysis for a six-month period ending June 30, 2020, indicates this is a financial report for a period shorter than a full fiscal year. The document length is substantial (15,000 characters), and it is not merely an announcement or a certification. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). H1 2020
2020-09-24 English
VOLUNTARY ANNOUNCEMENT - CSTONE ANNOUNCES PRELIMINARY RESULTS FROM A BRIDGING STUDY OF AVAPRITINIB IN CHINESE PATIENTS WITH UNRESECTABLE OR METASTATIC GASTROINTESTINAL STROMAL TUMORSAT THE 2020 CSCO A
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by CStone Pharmaceuticals presenting preliminary clinical trial results of a drug (avapritinib) at a medical conference (2020 CSCO Annual Meeting). It includes detailed clinical data, safety profile, and regulatory submission updates. The document is not a full financial report, audit, or earnings release. It is not a regulatory filing or certification. It is a corporate announcement focused on clinical trial results and regulatory progress, not related to shareholder meetings, capital changes, or legal matters. The document length is about 9,842 characters, which is substantial but it is clearly an announcement rather than a full report. The content fits best under a general regulatory announcement category since it does not fit other specific categories like earnings, annual report, or management changes. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2020-09-24 English
VOLUNTARY ANNOUNCEMENT - CSTONE ANNOUNCES UPDATED RESULTS FROM TWO STUDIES OF ITS ANTI-PD-L1 MONOCLONAL ANTIBODY SUGEMALIMAB (CS1001) AT 2020 CSCO ANNUAL MEETING
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by CStone Pharmaceuticals reporting updated clinical study results for their drug sugemalimab presented at the 2020 CSCO Annual Meeting. It contains detailed clinical trial data, efficacy and safety results, and commentary from the chief medical officer. There is no indication that this is a full annual or interim financial report, audit report, or earnings release. It is not a regulatory filing or certification. The document is an announcement of clinical trial results, which is typical for a voluntary announcement or a regulatory announcement related to clinical progress rather than financial or governance matters. Given the nature of the content and the fact it is an announcement rather than a full report, the best fitting category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous regulatory announcements that do not fit other categories. The document length (9998 characters) and content confirm it is not a brief report publication announcement or a short notice. Therefore, the classification is RNS with high confidence.
2020-09-24 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.